EyeCare Partners Looks Ahead Towards Latest Ophthalmology Breakthroughs at the American Academy of Ophthalmology (AAO) 2024 in Chicago

EyeCare Partners (ECP), the nation’s leading provider of clinically integrated eye care, announced today that its doctors will share key data and innovation at AAO 2024, the upcoming annual American Academy of Ophthalmology meeting. The Academy’s annual meeting takes place Friday, Oct. 18, through Monday, Oct. 21, at McCormick Place in Chicago.

“The innovation on display at AAO 2024 by our incredible eye care experts is a sight to behold,” said Daniel Miller, M.D., Ph.D., Ophthalmology Division President and Executive Medical Officer. “We’re proud to play a role in connecting these innovators through our EyeCare Partners network. Insights shared every year at AAO highlight the data-backed discoveries made possible when our world-class physicians come together. Our team is excited to share and learn more as we elevate eye care at this year’s meeting.”

The full lineup of AAO 2024 presenters can be found on the AAO’s website. More than two dozen EyeCare Partners physicians will be engaged in poster sessions, presentations, symposia, and skills-transfer and instruction courses.

Select highlights from ECP’s contributions to presentations and posters include:

• Home OCT Pivotal Study: Longitudinal Home Use and Visualization Agreement Between In-Office and Home OCT for nAMD – Miguel Busquets, M.D., Retina Associates of Kentucky
• Refractive Original Papers – Chaired by Elizabeth Yeu, M.D., Virginia Eye Consultants
• Advancing Ocular Health: AI-Driven Diagnosis and Subtype Discrimination in Microbial Keratitis Management – Albert Cheung, M.D., Virginia Eye Consultants
• AR-15512: A Novel TRPM8 Agonist for the Treatment of the Signs and Symptoms of Dry Eye: Phase 3 Pivotal Study Results – Edward Holland, M.D., Cincinnati Eye Institute
• Real-World Efficacy and Safety of Faricimab in nAMD: Two-Year Results of the TRUCKEE Study – Jeremy Wolfe, M.D., Associated Retinal Consultants
• Reduction in IOP After Switching to Latanoprostene Bunod in Glaucoma Patients in Real-World Clinical Practice – Constance Okeke (lead author), M.D., Virginia Eye Consultants